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ABSTRACT 
DNA methylation is a biochemical process catalyzed by enzyme DNA Methyltransferases 
(DNMTs). In most of the carcinogenesis DNMTs are over expressed and aberrant genomic 
DNA methylation pattern (genome wide hypomethylation and regional hypermethylation) are 
being observed. One of such consequences results in hypermethylation of Tumor Suppressor 
Genes. In different cancerous, different DNMTs show significantly elevated expression than 
their normal cells. In our study we have investigated relative expression of DNMTs and TSGs 
in normal and cancerous tissue. We found that DNMT3A expression level is comparatively 
more than the other DNMTs and it may cause the transcriptional repression of TSGs, 
particularly in lymph Node cancer. 
 
 
Key Words: DNA Methylation, DNA Methyltransferases, Tumor Suppressor Genes, Lymph 
Node Cancer. 
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PREFACE-“DNA: THE SECRET OF LIFE” 
On February the 28th 1953, James Watson and Francis Crick deciphered the structure of 
deoxyribonucleic acid, DNA1, which was later published in the journal Nature [1]. The DNA 
X-ray diffraction pictures made by Rosalind Franklin were essential for this discovery, as 
they provided several of the vital helical parameters [2]. The four separate building blocks of 
the DNA molecule, the nucleotides adenine, cytosine, guanine, and thymine, had been 
isolated and characterized several years before this immensely important discovery. The 
modified cytosine base, 5-methylcytosine, was first recognized in 1948 [3] and was later 
identified as a central element in the field of epigenetics2. The DNA contains the genetic 
instruction specifying how to assemble protein molecules, which are the building blocks of 
each phenotype. Indeed, Crick described the DNA molecule as “the secret of life”, and today 
several fields of research address DNA directly or indirectly. The most recent breakthrough 
in the history of DNA research has been the sequencing of the human genome [4, 5], which 
has heralded a new era for genetic as well as epigenetic research. The challenge now, is to 
understand the molecular mechanisms that allow specific genes and gene families to be 
selectively expressed in normal development and how aberrations in this process can lead to 
disease. In addition to well-described genetic mechanisms, imbalances in the epigenetic 
control of gene expression can profoundly alter this finely tuned machinery. Epigenetic 
changes are now recognized to have a lead role in cancer development [6]. Simultaneously, 
such changes have been hypothesized to be a master key to more effective ways of 
diagnosing, monitoring, and treating cancer [7]. On our way to molecular assisted medicine, 
we need to explore this in detail in order to get a better understanding of the role of epigenetic 
in cancer development, which is necessary to fully master these new tools. 
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INTRODUCTION 
What is a Cancer?: 
Organisms are maintained by homeostasis, a finely tuned balance between cell proliferation 
and cell death. When the homeostasis is disturbed, either by an increased proliferation rate or 
a decrease in cell death, a tumor might occur, which can further progress into a cancer. 
Tumor development is most commonly described as natural selection followed by clonal 
expansion, resulting in monoclonal tumors originating from the progeny of a single cell [8]. 
Aberrations that confer growth advantages to the cell will accumulate during the clonal 
selection process. These changes are consequences of several processes: 1) activation of 
proto-oncogenes, rendering the gene constitutively active or active under conditions in which 
the wild type gene is not, 2) inactivation of tumor suppressor genes, reducing or abolishing 
the activity of the gene product, 3) alteration of repair genes, which normally keep genetic 
alterations to a minimum. Genomic analyses focusing on structural and numerical aberrations 
of chromosomes have long suggested that cancer is, in essence, a genetic disease [9].  
The first cancer-specific genetic aberration described was the Philadelphia chromosome in 
patients with chronic myeloid leukemia. This was initially identified in 1960 by Nowell and 
Hungerford and was later demonstrated to be the result of a translocation between 
chromosomes 9 and 22 [10]. Today, numerous mutations at the chromosome and DNA level 
have been described in hematological as well as solid tumors [10, 11]. The Mitelman 
Database of Chromosome Aberrations in Cancer lists the chromosomal aberrations of more 
than 47,000 tumors [12], and the IARC mutation database have recorded 21,587 somatic 
mutations of the tumor suppressor gene TP53 [13].  
During the last decades, several lines of evidence have proven the importance also of 
epigenetic modifications in tumorigenesis.  Indeed, epigenetic changes are now recognized to 
be at least as common as genetic changes in cancer [6]. Moreover, epigenetic changes often 
precede and appear to be essential for several genetic events that drive tumor progression.  
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REVIEW OF LITRETURE 
Epigenetics: 
The term „epigenetic‟ was coined by Conrad Waddigton in 1940s to describe “the 
interactions of genes with their environment, which bring the phenotype into being” [14]. 
This early usage of the term has been effectively displaced during the last decades and today 
epigenetic inheritance is defined as cellular information, other than the DNA sequence itself, 
that is heritable during cell division i.e. “The sum of the alterations to the chromatin template 
that collectively establish and propagate different patterns of gene expression (transcription) 
and silencing from the same genome.”  [15]. Epigenetics affect the transcription in the cell, 
thereby controlling gene expression and abnormal epigenetic changes can have serious 
effects for the organism. Most epigenetic changes only occur within the course of one 
individual organism‟s lifetime, but, if a mutation in the DNA has been caused in gamete that 
result in fertilization, then some epigenetic changes are inherited from one generation to the 
next - “Lamarckism”. We can very roughly divide epigenetics into three substantially 
overlapping categories: DNA methylation, genomic imprinting, and histone modification. 
Among these mechanisms, DNA methylation is the most studied, and is the main focus of 
this thesis. 
DNA Methylation: 
DNA methylation is a covalent modification of nucleotides and the most frequently 
methylated nucleotide in the human genome is cytosine subsequently followed by a guanine 
in the DNA sequence, constituting a CpG dinucleotide. The cytosine is methylated in the C-5 
position by a family of DNA (cytosine-5) methyltransferases (DNMTs) using the universal 
methyl donor Sadenosyl- L-methionine (SAM) (Figure.1).  
 
Figure.1: Methylation of cytosine catalyzed by DNMTs. 
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5 methylcytosines account for about 1% of total DNA bases in the human genome and affects 
70-80% of the CpG sites in a human somatic cell [16]. Spontaneous deamination of 5-
methylcytosine to thymine [17] has during the evolution led to a great under-representation of 
CpG dinucleotides in the human genome. When unmethylated cytosine deaminates to uracil 
it will be excised by the enzyme DNA-uracil glycosylase, and the original sequence is 
restored by DNA repair enzymes. However, the DNA repair machinery does not recognize 
the thymines resulting from 5-methylcytosine deaminations. Hence, the spontaneous 
deamination of 5-methylcytosine leads to a C to T transition mutation in the genome [17] 
(Figure.2). A substantial fraction of the CpG dinucleotides left in the genome are located in 
CpG islands, which are GC-rich regions that possess high relative densities of CpG. They are 
mainly positioned at the 5' ends of many human genes and are usually unmethylated 
regardless of the expression status of the associated gene [18]. Recent reports using 
computational analyses suggests that there are at least 29,000 CpG islands in the human 
genome [5, 19]. Several CpG sites are also found within repetitive or parasitic intragenomic 
elements. In contrast to the CpG islands, the CpG sites located here are largely methylated 
[20], as are the majority of the remaining CpG sites scattered in the human genome. 
 
 
 
Figure.2: Introduction of mutation by spontaneous deamination of 5- methylcytosine. 
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DNA methylation as a gene silencing mechanism: 
The first connection between DNA methylation and gene expression was published more 
than 25 years ago [21]. Two mechanisms have been proposed to account for transcriptional 
repression via DNA methylation. In the first mechanism, DNA methylation directly inhibits 
the binding of transcription factors (TFs) such as AP-2, c-Myc/Myn, E2F and NFkB to their 
binding sites within promoter sequence. In this mechanism, CpG dinucleotides have to be 
present within the binding site of TFs, which are sensitive to methylation of CpG 
dinucleotides (Figure.3: A & B). 
 
Figure.3: Repression of transcription via CpG dinucleotide methylation. (Fujita N et.al.2000) 
The second mode of repression includes a binding of proteins specific for m5CpG 
dinucleotides to methylated DNA. Methylated DNA recruits m5CpG-binding (MeCP) and 
m5CpG-binding domain (MBD) proteins. MeCP1 and MeCP2 bind specifically to 
methylated DNA in whole genome and form spatial obstacle that unable binding of TFs to 
promoter sequences (Figure.3: C). MeCP1 represses transcription of specific genes, which are 
controlled by densely methylated promoters containing more than ten m5CpG dinucleotides. 
MeCP2 can bind to a single symmetrically located m
5
CpG pair in two DNA strands [22].  
These changes were inherited by the next generation of cells and it became obvious that 
reducing DNA methylation reactivated certain genes, allowing the development of new cells 
from the original embryo. Today, two different pathways have been described for the 
inactivation of gene transcription by DNA methylation:  
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       1) Methyl-CpGs can repel transcription factors directly by being present in the 
transcription factor binding sequence. Although regulation by such a mechanism in vivo is 
relatively rare, some transcription factors, like Ets-1 [23] and the boundary element factor 
CTCF [24] are unable to bind DNA if the cytosines in their recognition sites are methylated.  
     2) DNA methylation can recruit proteins that bind methylated CpGs and subsequent 
inhibit transcription by remodelling the chromatin structure. 
DNA Methyltransferases (DNMTs): 
The mammalian DNMTs family encompasses DNMT1, DNMT2, DNMT3A and DNMT3B. 
This family is divided into maintenance and de novo Methyltransferases. Maintenance 
DNMT1 binds methyl groups to the hemimethylated DNA during replication, whereas de 
novo DNMT3A and DNMT3B add methyl groups to CpG dinucleotides of unmethylated 
DNA (Figure.4). 
       
 
Figure.4: Methylation Pattern in genomic DNA. T.H. (Bestor et.al-1988, Xie S et.al.-1999) 
DNMT1, DNMT3A and DNMT3B are required for formation of the established pattern of 
methylation in promoters and first exons of human genomic DNA [25]. In somatic cells, the 
pattern of DNA methylation is highly conservative and during cell division is kept by 
maintenance DNA methyltransferase (DNMT1) [25, 26, 27]. This enzyme is a component of 
DNA replication complex[28] and maintains the DNA methylation via addition of a methyl 
group to the 5-position of the cytosine ring within the CpG dinucleotides of newly 
synthesized DNA strand. DNMT1 forms three isoforms, which were found in somatic cells, 
pachytene spermatocytes, oocytes and preimplantation embryos. These transcript isoforms 
are produced by alternative usage of multiple first exon of DNMT1 primary transcript [29]. 
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DNMT3A and DNMT3B enzymes are responsible for establishment of new methylation 
pattern in genomic DNA (Figure.4.B) [30, 31 & 25]. 
Mammalian DNMT1, DNMT3A and DNMT3B are composed of the N-terminal regulatory 
and the C-terminal catalytic domains that are linked by a short fragment of repeated GK 
dipeptides (Figure.5). The N-terminal domains of DNMT1 and DNMT3B do not exhibit 
extensive homolog of primary structure. These differences are responsible for distinct 
functions of N-regions in these enzymes. The DNMT1 requires interaction between the N- 
and C-terminal domains for catalytic activity. Separated C-terminal domain of DNMT1 is 
catalytically inactive despite the presence of the highly conserved sequence motifs typical of 
active DNMTs. In contrast to DNMT1, C-terminal domain of DNMT3A and DNMT3B is 
active without interaction with their N-regulatory regions. These differences between 
DNMT1 and de novo DNMTs indicate significantly disparate mechanism that regulate 
methylation activity of these enzymes. 
 
Figure.5: Members of mammalian DNMTs family. (Weisenberger DJ, et.al.-2004) 
The N-terminal domain possesses nuclear localization signal sequence (NLS) responsible for 
localization of DNMTs in the nucleus. The N-fragment of DNMTs also contains proliferating 
cell nuclear antigen binding domain (PDB), a cysteine rich zinc finger DNA binding motif 
(ATRX), and polybromo homology domain (PHD) targeting DNMTs to the replication foci. 
However, PWWP tetrapeptide is only present in N-terminal domains of DNMT3A and 
DNMT3B and interact with histones [32]. The C-terminal domain contains six conservative 
motifs I, IV, VI, VIII, IX and X. Motifs I and X form S-adenosylomethionine binding site, 
motif IV binds cytosine at the active site, motif VI possesses glutamyl residue donating 
protons, and motif IX maintains the structure of the target recognition domain (TRD) usually 
located between motifs VIII and IX, that makes base-specific contacts in the major groove of 
DNA [33, 34, 35, 36]. 
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DNMTs & TUMOR SUPRESSOR GENES (TSGs) IN CANCER: 
DNA hypermethylation is responsible for epigenetic inactivation of TSGs expression in 
cancer cells. Increase in mRNA and protein biosynthesis of DNMT1 and DNMT3B in 
various cancer types significantly correlates with hypermethylation of CpG islands located in 
the promoter regions of various TSGs (Table.1). Methylation of these TSG promoters is 
associated with the complete loss of TSG protein products in cancer cells and development of 
malignant phenotype [37]. 
Etoh et al. [38] showed in gastric cancer cells significantly reduced expression of the 
CDKN2A, MLH1, and cell-cell adhesion protein encoded by CDH1 gene. Loss of expression 
of mRNAs and proteins of TSGs correlated with intracellular elevation of DNMT1 content 
and complete methylation of the CDKN2A, MLH1 and CDH1 promoters in gastric cancer 
cells. Similar relationship between DNMT1 and DNMT3B expression and CDH1 promoter 
methylation was observed by Girlaut et al. [39] in breast carcinoma. Increased expression of 
DNMT1 and DNMT3B were also correlated with the increase in breast cancer aggressiveness 
[39]. The epigenetic inactivation of CDKN2A and MLH1 genes expression was also 
associated with increased level of DNMT1 and DNMT3B contents in colon cancer cells [40]. 
TSGs Functions 
Cancer type with 
identified 
hypermethylation 
References 
BRCA1 DNA damage repair Breast, Ovarian [41] 
CDH1 Cell-Cell adhesion Breast, Prostrate, 
Colorectal 
[42, 43] 
CDKN2A Cyclin dependent 
kinase inhibitor 
Lymphoma [44] 
CDKN2B Leukemia [45] 
RB1 Represses the 
transcription of 
cellular genes 
Retinoblastoma [46] 
TP53 Cell cycle regulation Leukemia [47] 
Table.1: TSGs promoter methylation pattern in cancer. 
 “Role of DNMT in Cancer” 
 
 Page 9 
 
OBJECTIVE 
To clarify the role of DNMTs in the aberrant promoter hypermethylation of TSGs in various 
human cancers, the expression levels of a number of DNMTs in cancer tissues were 
examined and were correlated with the findings of the promoter methylation status of p53 
TSGs which is commonly involved in cellular regulatory pathways. The expressions of the 
DNMTs, DNMT1, DNMT2, DNMT3A and DNMT3B were examined, since these enzymes 
have a reported role in the maintenance of the genome methylation status integrity and have 
been implicated in the transcriptional regulatory changes of human cancer.  
So our main objective was “Comparative Analysis of DNA Methyltransferase (DNMTs) 
Expression and Promoter Hypermethylation of Tumor Suppressor (TSGs) Genes in 
Normal and various Human Cancer Tissues”. 
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MATERIALS AND METHODS 
SAMPLE COLLECTION: 
To achieve our objective, blood was collected from CWS Hospital, Rourkela as normal 
human tissue and cancer tissues (Gall Bladder and Lymph Node) from CMC, Kolkata. 
TOTAL RNA ISOLATION: 
     Chemical Reagents and Buffer:- 
 TRIzol Reagents (Sigma), 
 Choloroform, 
 Isopropanol, 
 Ethanol (70%), 
 Denaturation Buffer- 50 % deionized formamide, 
          ,                                               2.2 M formaldehyde, 
              MOPS buffer (pH 7.0), 
              6.6 % glycerol, 
              0.5 % bromphenol,  
 Ethidium Bromide, 
 Agarose, 
     
 Protocol:- 
 Transfered 50-100 mg of frozen tissue in a 2 ml tube with 1 ml TRIzol. 
 Homogenized for 60 sec in the polytron 
 Added 200 l chloroform 
 Mixed by inverting the tube for 15 sec 
 Incubated for 3 min at room temperature 
 Centrifuged at 12.000 g for 15 min 
 Transfered the aqueous phase into a fresh Eppi tube 
 Added 500 l isopropanol 
 Centrifuged at max. 12.000 g for 10 min in the cold room 
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 Washed the pellet with 500 l 70 % ethanol 
 Centrifuged at max. 7.500 g for 5 min in the cold room 
 Dried the pellet on air for 10 min 
 Disolved the pellet in 50-100 l DEPC-H2O 
 Incubated for 10 min at 60 C 
 Took spectrophotometer reading 
 And analysed the RNA on a MOPS gel:  
                                  -Disolved 1-3 g RNA in 11 l denaturation buffer 
                              - Added 1 l ethidium bromide (1mg/ml) and denaturate at 65 C for 15 min 
                              - Loaded a 1 % agarose gel in MOPS buffer plus 5 % formaldehyde 
                           - Run the gel at 40 V for 4 h 
 
cDNA SYNTHESIS: 
    Chemical Regents and Buffer:- 
 5X First Strand Buffer 
 10mM dNTP Set 
 0.1M DTT 
 Random Primers 
 RNaseOUT Ribonuclease Inhibitor 
 SuperScript II RNase H- Reverse Transcriptase 
      
      Protocol:- 
 Took 8µl of total RNA. 
 Then added 3 μl Random Primers. 
 Added 1 μl dNTP mix. 
 Vortex and then spin down tube. 
 Incubated at 65°C for 5 min. 
 Placed tube on ice. 
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 Added 4 μl 5X Buffer, 2 μl DTT and 1μl RNAseOut. 
 Vortex and then spin down tube. 
 Incubated at 42°C for 1 min. 
 Added 1μl SuperScript II RNase H- Reverse Transcriptase. 
 Incubated at 42°C for 60 min. 
 Incubated at 70°C for 15 min. 
 Added 180 μl molecular grade water. 
 Store at -80°C. 
GENE SPECIFIC PCR: 
     Primers:-      
Gene 
Name 
Sense Primer Antisense Primer Tm 
DNMT1 ACCAAGCAAGAAGTGAAGCC GCTTCCTGCAGAAGAACCTG 63.3 & 
64.0 
DNMT3A CACACAGAAGCATATCCAGGAGTG AGTGGACTGGGAAACCAAATACCC 66.7 & 
68.5 
DNMT3B AATGTGAATCCAGCCAGCCAGGAA
AGGC 
ACTGGATTACACTCCAGGAACCGT 77.9 & 
67.6 
p53 GTCACTGCCATGGAGGAGCCGCA GACGCACACCTATTGCAAGCAAGGGTTC 78.2 & 
76.1 
Β-Actin TCTACAATGAGCTGCGTGTG ATCTCCTTCTGCATCCTGTC 62.7 & 
60.8 
 
    
 
 
 
[Patra et.al, 2002. Dolidrup et.al, 2007] 
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PCR Mixture:- (Total 25µl) 
 0.2 µM dNTP- 0.5µl 
 1.5 mM MgCl2- 1.5µl 
 1x PCR Buffer- 2.5µl 
 Taq Polymearse (5U/µl)- 0.5µl 
  Primers (0.2µM)- 0.5µl & 0.5µl 
 cDNA- 2µl 
 MQ Water- 17µl 
   PCR Condition:- 
                 94
o
C1:00[94
o
 C0:20; 57˚C0:20; 72
o
C 0.30]30; 72
o
C 5:00   for DNMT3B. 
                 94
o
C1:00[94
o
 C0:20; 65˚C0:20; 72
o
C 0.30]30; 72
o
C 5:00   for DNMT3A. 
                 94
o
C1:00[94
o
 C0:20; 58˚C0:20; 72
o
C 0.30]30; 72
o
C 5:00   for DNMT1. 
                 94
o
C1:00[94
o
 C0:30; 60˚C0:45; 72
o
C 1.30]30; 72
o
C 5:00   for p53. 
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RESULTS & DISCUSSON 
From Normal Tissue (Blood): 
Product Conc
n
.
 
(µg/ml) Purity 
260/280 260/230 
Total RNA 570.32 1.34 0.82 
Table.2: Spectrophotometer results of total RNA from blood tissue 
 
 
 
 
 
 
 
 
Gene Conc
n
.
 
(µg/ml) Purity 
260/280 260/230 
DNMT1 263.25 1.71 1.03 
DNMT3A 286.69 1.79 0.96 
DNMT3B 301.58 1.83 0.89 
p53
 
276.23 2.01 0.86 
Β-Actin 401.35 1.93 1.02 
Table.3: Spectrophotometer results of gene specific amplification product from blood 
 
 
[Total RNA in 1% agarose gel] 
[Total RNA in denaturation gel] 
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From Cancerous Tissue: 
Tissue Conc
n
.
 
(µg/ml) Purity 
260/280 260/230 
Gall Bladder Cancer 234.67 1.03 0.65 
Lymph Node Cancer 478.51 1.61 1.02 
Table.4: Spectrophotometer results of total RNA from cancerous tissue 
 
                                                         
                                                Lane.1: Lymph Node Cancer 
                                                        Lane.2: Gall Bladder Cancer         
 
 
 
 
 
1          2 
[Total RNA in denaturation gel] 
     1              2             3             4 
[Gene specific PCR amplification] 
Lane.1- β-actin 
Lane.2- DNMT3A 
Lane.3-DNMT3B 
Lane.4-p53 
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Table.5: Spectrophotometer results of gene specific amplification product from lymph node 
cancer tissue  
 
 
 
 
 
 
 
 
 
 
 
Gene Conc
n
.
 
(µg/ml) Purity 
260/280 260/230 
DNMT1 168.23 1.74 1.28 
DNMT3A 353.78 1.87 1.31 
DNMT3B 326.69 1.69 1.25 
p53
 
65.21 1.57 0.92 
Β-Actin 395.35 1.73 1.19 
[Gene specific PCR amplification] 
1     2        3       4       5      6     7   
   8          9         10      11 
Lane.7 & 11- Marker 
Lane.1 & 8- β-actin 
Lane.3- DNMT1 
Lane.5-p53 
Lane.9- DNMT3A 
Lane.10- DNMT3B 
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[Comparative Study of Expression Level in both Normal & Cancer Tissue] 
After isolation the total RNA from normal blood and Cancerous tissue, we checked their 
concentration by taking its OD in spectrophotometer, in case of Gall Bladder the 
concentration was found to be very low i.e. 234.67µg/ml, which was very low compare to the 
other samples reading. Because it was took a lot of time to processing after collecting the 
sample and also cDNA was not synthesize from the total RNA by rt-PCR method due to 
some unsuitable condition. 
It was observed, after gene specific amplification there amazing results were found. These 
were the concentration of DNMT3A and DNMT3B i.e. 286.69 and 301.58 respectively in 
normal blood cells, but in cancerous tissue the concentration were found to increase i.e. 
312.78 and 353.69 respectively. And TSG i.e p53 concentration was 376.23 µg/ ml in normal 
blood cells, but in cancerous tissue it was so much lowered i.e.109.21 µg/ml. 
 
 
 
 
 
 
 
0
50
100
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300
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400
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CONCLUSION 
 
As observed from the above results, DNMTs are over express in Lymph Node cancer tissue. 
So from this we can hypothesize that these over expression of DNMTs leads to 
hypermethylation of TSG (for example, p53), which in turn diminish the expression of p53 
and causing the cancer. 
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FUTURE WORK 
The role of DNMTs in causing cancer through its effects on TSGs can be further confirmed 
by carrying out by bisulphate modification and methylation specific-PCR (MS-PCR) of the 
respective genes. This can help to locate the exact methylation site on the TSGs promoters.  
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